The Physicians

Every patient under consideration for HIPEC is thoroughly evaluated by the multidisciplinary team of the Perlmutter Cancer Center. Our group of Surgical Oncologists is supported by colleagues in Medical Oncology, Gastroenterology, and Radiology – all with specific expertise in intraperitoneal chemotherapy. Each case is discussed in detail and imaging studies are reviewed at our weekly GI Oncology Conference. This integrated approach ensures the best care, both now and long-term, for all of our patients.


Marcovalerio Melis, MD, FACS

Dr. Melis completed his fellowship in Surgical Oncology at the Moffit Cancer Center in Florida. He has developed a HIPEC treatment program at the Manhattan VA Hospital, which now serves as the regional treatment center for peritoneal surface malignancies. Dr. Melis is the director of a current trial investigating the role of HIPEC in patients at high-risk for carcinomatosis.




Russell Berman, MD, FACS

Dr. Berman obtained his general surgery residency training at NYU. He was a Research Fellow at Memorial Sloan Kettering Cancer Center, and later completed a clinical fellowship in Surgical Oncology at the MD Anderson Cancer Center. Dr. Berman has been involved with HIPEC since it was first approved; he participated in the early investigational studies of HIPEC at MD Anderson Cancer Center.